in the absence of a submission from the holder of the marketing authorisation:
ofatumumab (Arzerra®) is not recommended for use within NHS Scotland.
Indication under review: Treatment of adult patients with relapsed CLL in combination with fludarabine and cyclosphosphamide.
The holder of the marketing authorisation has not made a submission to SMC regarding this product in this setting. As a result we cannot recommend its use within NHSScotland.
|Drug Name:||ofatumumab (Arzerra)|
|SMC Drug ID:||1237/17|
|Manufacturer:||Novartis Pharmaceuticals UK Ltd|
|Indication:||Treatment of adult patients with relapsed CLL in combination with fludarabine and cyclosphosphamide.|
|Sub Category:||8.2 Drugs affecting the immune response|
|Submission Type:||Non submission|
|Date Advice Published:||10 April 2017|